Commentary "A CAR against rejection: dual-targeting allogeneic T cells"
vor 4 Stunden
1 Min. Lesezeit
Philip and Josef wrote a commentary to the Blood journal article "A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study" https://doi.org/10.1182/blood.2025032112
In their commentary, they summarize the work by Jin et al on clinical proof-of-concept multilayered genetic engineering for allogeneic/off-the-shelf CAR T cell therapy.
Check out the commentary: https://doi.org/10.1182/blood.2026034919
